Bacilli State PD-1 inhibitor tislelizumab shows remarkable efficacy in the treatment of classic Hodgkin lymphoma

recently, Baiji Shenzhou released a key clinical data at theof the ASHConference(http:// whose PD-1 inhibitor tislelizumab showed remarkable efficacy in treating classic Hodgkin's lymphoma with resistance in the pastin thetrial(http://, patients injected 200 mg of tislelizumab every three weeks and used PET imaging to assess the trial response rateThe data show that the overall response rate is 86%, of which the full response rate is as high as 60%The median duration and progression lifetime have not yet been reachedin 4 out of 70 patients with severe adverse events (AE), and about 1 in 5 patients had level 3 or 4 AE, and no deaths related to the drug had occurredOpdivo and keytruda's overall response rate for the treatment of classic Hodgkin's lymphoma was about 69%, with a full response rate of only 20% to 30%, and the published tislelizumab data significantly improved in terms of full response rate, and the results of further Phase III amplification trials are to be expectedEric Hedrick, chief scientific adviser to, said that the special thing that tislelizumab was designed to be designed was that it specifically removed its binding to the Fc gamma receptor, thus avoiding the activation of macrophages that can kill the effect of T-cellsHedrick also said there are some important differences in clinical trials in China compared to Keytruda and OpdivoFor example, Western patients typically use Seattle Genetics' Adcetris for pretreatment, which is not used in ChinaTislelizumab will also conduct further clinical trials in cancers such as metastatic or metastatic bladder urination, esophageal cancer, stomach cancer or gastroesophageal co-operative cancer